| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | UBCH10; dJ447F3.2 |
| Entrez GeneID | 11065 |
| clone | 1F5D3 |
| WB Predicted band size | 19.7kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human UBE2C (AA: FULL(1-179)) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于UBE2C抗体的示例参考文献(内容为虚构，仅供参考，建议通过学术数据库验证具体文献)：
---
1. **文献名称**: *"A monoclonal antibody against UBE2C for detection of tumor progression in breast cancer"*
**作者**: Li X, Wang Y, Chen J
**摘要**: 该研究开发了一种针对UBE2C的单克隆抗体，用于乳腺癌组织样本的免疫组化分析。结果显示，UBE2C高表达与肿瘤分期和患者生存率降低显著相关，提示其作为预后生物标志物的潜力。
2. **文献名称**: *"UBE2C-specific antibody validation in cell cycle regulation studies"*
**作者**: Smith R, Patel K, Lee H
**摘要**: 本文验证了一种商业化UBE2C抗体在Western blot和免疫荧光中的特异性，证实UBE2C在有丝分裂退出中的关键作用，并发现其敲低导致癌细胞周期停滞。
3. **文献名称**: *"Development of a novel polyclonal antibody for UBE2C in hepatocellular carcinoma diagnosis"*
**作者**: Zhang L, Tanaka M, Kim S
**摘要**: 研究者开发了一种兔源多克隆抗体，用于肝癌组织中UBE2C的检测。通过质谱验证抗体特异性，并发现UBE2C过表达与肝癌患者术后复发风险升高相关。
4. **文献名称**: *"Comparative analysis of UBE2C antibodies in colorectal cancer biomarker studies"*
**作者**: Gupta A, Rodríguez A, Müller R
**摘要**: 对比了四种市售UBE2C抗体在结直肠癌免疫组化中的性能，发现抗体克隆号#AB123在不同样本中一致性最佳，为临床研究提供标准化工具。
---
**建议**：通过PubMed或Google Scholar搜索关键词“UBE2C antibody validation”、“UBE2C immunohistochemistry”或“UBE2C biomarker”获取真实文献。
The UBE2C antibody is a crucial tool for studying the ubiquitin-conjugating enzyme E2C, a member of the E2 ubiquitin-conjugating enzyme family. UBE2C, also known as UBCH10. plays a pivotal role in the ubiquitin-proteasome system (UPS), which regulates protein degradation and cellular processes like cell cycle progression, DNA repair, and apoptosis. Specifically, UBE2C interacts with the anaphase-promoting complex/cyclosome (APC/C), a multi-subunit E3 ligase, to mediate the ubiquitination of mitotic regulators such as cyclins and securins. This activity is essential for proper mitotic exit and chromosomal segregation.
Dysregulation of UBE2C is linked to carcinogenesis, as its overexpression is observed in various cancers (e.g., breast, lung, colorectal), correlating with uncontrolled proliferation, genomic instability, and poor prognosis. Researchers use UBE2C antibodies in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect its expression levels, subcellular localization, and interactions in both normal and pathological tissues. These antibodies aid in elucidating UBE2C’s role in tumorigenesis, drug resistance, and as a potential therapeutic target. Commercial UBE2C antibodies are typically validated for specificity and sensitivity, with monoclonal antibodies offering high reproducibility. Ongoing studies focus on developing UBE2C inhibitors and exploring its utility as a biomarker for cancer diagnosis and treatment monitoring.
×
